Echinocandins for Primary Therapy of Candidemia: Time for a Paradigm Shift?

Rhonda E. Colombo, Jose Antonio Vazquez

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Candidemia is a common healthcare-associated bloodstream infection that is continuing to increase in incidence. Candidemia is associated with significant morbidity and mortality, which may be potentiated by delays in the initiation of early and appropriate therapy. Recently, the epidemiology of candidemia has shifted, and infections due to non-albicans Candida species as the causative pathogens have increased in frequency. Several studies have been published over the past 5 years in relation to the management of candidemia. Echinocandins have demonstrated favorable clinical responses with a low incidence of adverse effects in patients with candidemia due to both Candida albicans and non-albicans Candida species and, as such, have emerged as the preferred initial therapy.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalCurrent Fungal Infection Reports
Volume9
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Echinocandins
Candidemia
Candida
Therapeutics
Incidence
Cross Infection
Secondary Prevention
Candida albicans
Epidemiology
Morbidity
Mortality
Infection

Keywords

  • Candidemia
  • Echinocandins
  • Primary therapy

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Echinocandins for Primary Therapy of Candidemia : Time for a Paradigm Shift? / Colombo, Rhonda E.; Vazquez, Jose Antonio.

In: Current Fungal Infection Reports, Vol. 9, No. 1, 2015, p. 15-22.

Research output: Contribution to journalArticle

@article{84af3e9bf7704b708812458f4d058445,
title = "Echinocandins for Primary Therapy of Candidemia: Time for a Paradigm Shift?",
abstract = "Candidemia is a common healthcare-associated bloodstream infection that is continuing to increase in incidence. Candidemia is associated with significant morbidity and mortality, which may be potentiated by delays in the initiation of early and appropriate therapy. Recently, the epidemiology of candidemia has shifted, and infections due to non-albicans Candida species as the causative pathogens have increased in frequency. Several studies have been published over the past 5 years in relation to the management of candidemia. Echinocandins have demonstrated favorable clinical responses with a low incidence of adverse effects in patients with candidemia due to both Candida albicans and non-albicans Candida species and, as such, have emerged as the preferred initial therapy.",
keywords = "Candidemia, Echinocandins, Primary therapy",
author = "Colombo, {Rhonda E.} and Vazquez, {Jose Antonio}",
year = "2015",
doi = "10.1007/s12281-014-0215-9",
language = "English (US)",
volume = "9",
pages = "15--22",
journal = "Current Fungal Infection Reports",
issn = "1936-3761",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Echinocandins for Primary Therapy of Candidemia

T2 - Time for a Paradigm Shift?

AU - Colombo, Rhonda E.

AU - Vazquez, Jose Antonio

PY - 2015

Y1 - 2015

N2 - Candidemia is a common healthcare-associated bloodstream infection that is continuing to increase in incidence. Candidemia is associated with significant morbidity and mortality, which may be potentiated by delays in the initiation of early and appropriate therapy. Recently, the epidemiology of candidemia has shifted, and infections due to non-albicans Candida species as the causative pathogens have increased in frequency. Several studies have been published over the past 5 years in relation to the management of candidemia. Echinocandins have demonstrated favorable clinical responses with a low incidence of adverse effects in patients with candidemia due to both Candida albicans and non-albicans Candida species and, as such, have emerged as the preferred initial therapy.

AB - Candidemia is a common healthcare-associated bloodstream infection that is continuing to increase in incidence. Candidemia is associated with significant morbidity and mortality, which may be potentiated by delays in the initiation of early and appropriate therapy. Recently, the epidemiology of candidemia has shifted, and infections due to non-albicans Candida species as the causative pathogens have increased in frequency. Several studies have been published over the past 5 years in relation to the management of candidemia. Echinocandins have demonstrated favorable clinical responses with a low incidence of adverse effects in patients with candidemia due to both Candida albicans and non-albicans Candida species and, as such, have emerged as the preferred initial therapy.

KW - Candidemia

KW - Echinocandins

KW - Primary therapy

UR - http://www.scopus.com/inward/record.url?scp=84925498264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925498264&partnerID=8YFLogxK

U2 - 10.1007/s12281-014-0215-9

DO - 10.1007/s12281-014-0215-9

M3 - Article

AN - SCOPUS:84925498264

VL - 9

SP - 15

EP - 22

JO - Current Fungal Infection Reports

JF - Current Fungal Infection Reports

SN - 1936-3761

IS - 1

ER -